Karvea (Irbesartan)

• Karvea (irbesartan) is used to manage conditions related to the renin‑angiotensin system.
• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Diabetic nephropathy: slows the decline of renal function in adults with type 2 diabetes.
• Proteinuria associated with diabetic kidney disease: reduces urinary protein excretion, helping preserve kidney health.

• Irbesartan selectively antagonizes angiotensin II type 1 (AT1) receptors on vascular smooth muscle, adrenal gland, and renal tubular cells. By blocking these receptors, it prevents angiotensin II‑mediated vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
• Diarrhea: loose stools occurring intermittently.
• Nausea: feeling of queasiness or urge to vomit.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
• Hyperkalemia: elevated blood potassium levels that can affect heart rhythm.
• Acute kidney injury: sudden reduction in kidney function, indicated by rising creatinine.
• Hepatic injury: abnormal liver enzyme elevations or jaundice.
• Severe hypotension: markedly low blood pressure causing faintness or shock.
• Myocardial infarction: rare occurrence of heart attack symptoms.

• Before initiating therapy, clinicians should assess renal function, electrolyte status, and hepatic health.
• Monitor renal function: check serum creatinine and eGFR periodically.
• Monitor serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents.
• Avoid in severe hepatic impairment: use with caution as metabolism may be altered.
• Use caution in volume depletion: patients on diuretics may experience excessive blood pressure drops.
• Pregnancy: not recommended due to limited safety data; discuss risks with a healthcare provider.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use can increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.
• ACE inhibitors (e.g., enalapril): concurrent use heightens the chance of angioedema and renal dysfunction.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and affect kidney function.
• Lithium: irbesartan may increase lithium concentrations, necessitating serum level monitoring.